# EDGAR Filing Document

**Accession Number:** 0000748592
**File Stem:** 0001641172-25-014724
**Filing Date:** 2025-6
**Character Count:** 23578
**Document Hash:** b17c2ac89fc3eaa507796841f7055e35
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-014724.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001641172-25-014724

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**EFFECTIVENESS DATE**: 20250611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ernexa Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0000748592
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 311103425
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-287955
- **FILM NUMBER:** 251040534

**BUSINESS ADDRESS:**
- **STREET 1:** 1035 CAMBRIDGE STREET
- **STREET 2:** SUITE 18A
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** (617) 798-6700

**MAIL ADDRESS:**
- **STREET 1:** 10531 4S COMMONS DRIVE
- **STREET 2:** SUITE 166-550
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eterna Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20221017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brooklyn ImmunoTherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210325

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NTN BUZZTIME INC
- **DATE OF NAME CHANGE:** 20051230

**As filed with the Securities and Exchange Commission on June 11, 2025**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**Ernexa Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **31-1103425** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **1035 Cambridge Street, Suite 18A** |  |
| **Cambridge, MA 02141** | **02141** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**RESTATED 2020 STOCK INCENTIVE PLAN, AS AMENDED**

**(Full title of the plan)**

**Sanjeev Luther, President and Chief Executive Officer**

**Ernexa Therapeutics Inc.**

**1035 Cambridge Street, Suite 18A Cambridge, MA 02141**

**(Name and address of agent of service)**

(617) 798-6700

**(Telephone number, including area code, of agent for service)**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

*Ernexa Therapeutics Inc. Restated 2020 Stock Incentive Plan*

 

This registration statement registers 2,569,292 additional shares of common stock, par value $0.005 per share (the "Common Stock") of Ernexa Therapeutics Inc. (the "Registrant") under the Registrant's Restated 2020 Stock Incentive Plan, as amended (the "Plan"), which were added to the shares authorized for issuance under the Plan as of January 1, 2025 pursuant to an "evergreen" provision.

The contents of the previous Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the "Commission") for the Plan on June 3, 2021 (File No. 333-256760), October 12, 2021 (File No. 333-260200) and January 16, 2024 (File No. 333-276521), to the extent not otherwise amended or superseded by the contents hereof, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information specified in Part I of Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the "Securities Act") and the introductory note to Part I of the Form S-8 instructions. The documents containing the information specified in Part I will be delivered to the participants in the Plan covered by this Registration Statement as required by Rule 428(b)(1) under the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference.**

The following documents of the Registrant filed with the Commission are incorporated by reference in this Registration Statement as of their respective dates:

(a) the Registrant's Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/form10-k.htm) for the fiscal year ended December 31, 2024, filed with the SEC on March 12, 2025;

(b) the Registrant's Quarterly Report on [Form 10-Q](https://www.sec.gov/Archives/edgar/data/748592/000164117225009044/form10-q.htm) filed with the SEC on May 7, 2025;

(c) the Registrant's Current Reports on Form 8-K, filed with the SEC on [January 3, 2025](https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/form8-k.htm), [January 10, 2025](https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/form8-k.htm), [February 13, 2025](https://www.sec.gov/Archives/edgar/data/748592/000149315225006446/form8-k.htm), [March 12, 2025](https://www.sec.gov/Archives/edgar/data/748592/000149315225010049/form8-k.htm), [March 24, 2025](https://www.sec.gov/Archives/edgar/data/748592/000164117225000300/form8-k.htm), [March 26, 2025](https://www.sec.gov/Archives/edgar/data/748592/000164117225000681/form8-k.htm), [April 3, 2025](https://www.sec.gov/Archives/edgar/data/748592/000164117225002514/form8-k.htm), [June 2, 2025](https://www.sec.gov/Archives/edgar/data/748592/000164117225013249/form8-k.htm) and [June 9, 2025](https://www.sec.gov/Archives/edgar/data/748592/000164117225014318/form8-k.htm);

(d) The description of our common stock contained in our Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/748592/000114036121038578/ny20001244x2_8a12b.htm), registering our common stock under Section 12(b) under the Exchange Act, filed with the SEC on November 18, 2021.

All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>") (other than information furnished under Item 2.02, 7.01 or 9.01 of Form 8-K and exhibits furnished on such form that relate to such items unless such form expressly provides to the contrary) prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement.

**Item 4.** **Description of Securities.**

Not applicable.

**Item 5.** **Interests of Named Experts and Counsel.**

Not applicable.

**Item 6.** **Indemnification of Directors and Officers.**

Section 102 of the General Corporation Law of the State of Delaware (the "DGCL") permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our restated certificate of incorporation provides that, to the extent permitted by law, no director shall be liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, subject to the exceptions referenced in DGCL Section 102.

Section 145(a) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

Section 145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.

Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section 145 of the DGCL.

Our restated certificate of incorporation provides that we will indemnify, in the manner and to the full extent permitted by law, any person (or the estate of any person) who was or is a party, or is threatened to be made a party to, any threatened, pending or completed action, suit or proceeding, and whether civil, criminal, administrative, investigative or otherwise, by reason of the fact that such person is or was our director, officer, employee or agent, or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. Where required by law, the indemnification provided for shall be made only as authorized in the specific case upon a determination in the manner provided by law, that indemnification of the director, officer, employee or agent is proper under the circumstances. We may, to the full extent permitted by law, purchase and maintain insurance on behalf of any such person against any liability which may be asserted against him. To the full extent permitted by law, the indemnification provided shall include expenses (including attorneys' fees) in any action, suit or proceeding, or in connection with any appeal therein, judgments, fines and amounts paid in settlement, and in the manner provided by law any such expenses may be paid by us in advance of the final disposition of such action, suit or proceeding. The indemnification described herein does not limit our right to indemnify any other person for any such expense to the full extent permitted by law, nor is it exclusive of any other rights to which any person seeking indemnification from us may be entitled under any agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office.

The board of directors has approved a form of indemnification agreement that has been executed by each of our directors and executive officers. In general, these agreements each provide that we will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or executive officer of our company or in connection with their service at our request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain presumptions that are favorable to the director or executive officer. We also maintain a general liability insurance policy, which will cover certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.

**Item 7.** **Exemption from Registration Claimed.**

Not applicable.

Item 8. Exhibits.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br>**Number** | <br>**Exhibit Description** | **Filed**<br>**Herewith** | **Incorporated**<br> **by Reference**<br> **herein from Form or**<br>**Schedule** | **Filing**<br>**Date** | **SEC File/**<br>**Reg. Number** |
| 5.1 | [Opinion of Sichenzia Ross Ference Carmel LLP](ex5-1.htm) | X |  |  |  |
| 10.1 | [Ernexa Therapeutics Inc. Restated 2020 Stock Incentive Plan.](https://www.sec.gov/Archives/edgar/data/748592/000114036121030987/brhc10028852_ex99-1.htm) |  | Form 8-K<br> (Exhibit 99.1) | 09/13/2021 | 001-11460 |
| 23.1 | [Consent of Sichenzia Ross Ference Carmel LLP (included in opinion of counsel filed Exhibit 5.1).](ex5-1.htm) | X |  |  |  |
| 23.2 | [Consent of Grant Thornton LLP, independent registered public accounting firm.](ex23-2.htm) | X |  |  |  |
| 24.1 | [Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement).](#poa_001) | X |  |  |  |
| 107 | [Filing Fee Table.](ex107.htm) | X |  |  |  |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on June 11, 2025.

---

| | |
|:---|:---|
| **ERNEXA THERAPEUTICS INC.** | **ERNEXA THERAPEUTICS INC.** |
| By: | */s/ Sanjeev Luther* |
|  | Sanjeev Luther |
|  | President and Chief Executive Officer |

---

Each person whose signature appears below constitutes and appoints Sanjeev Luther and Sandra Gurrola, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Ernexa Therapeutics Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Sanjeev Luther* | President, Chief Executive Officer and Director | June 11, 2025 |
| Sanjeev Luther | (Principal Executive Officer) |  |
| */s/ Sandra Gurrola* | Senior Vice President, Finance | June 11, 2025 |
| Sandra Gurrola | (Principal Financial and Accounting Officer) |  |
| */s/ James Bristol* | Director | June 11, 2025 |
| James Bristol |  |  |
| */s/ Peter Cicala* | Director | June 11, 2025 |
| Peter Cicala |  |  |
| */s/ Dr. Elena Ratner* | Director | June 11, 2025 |
| Dr. Elena Ratner |  |  |
| /s/ *William Wexler* | Director | June 11, 2025 |
| William Wexler |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

June 11, 2025

***VIA ELECTRONIC TRANSMISSION***

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Re: Ernexa Therapeutics Inc. Form S-8 Registration Statement

Ladies and Gentlemen:

We refer to the above-captioned registration statement on Form S-8 (the "Registration Statement") under the Securities Act of 1933, as amended (the "Securities Act"), filed by Ernexa Therapeutics Inc., a Delaware corporation (the "Company"), with the Securities and Exchange Commission, pursuant to which the Company is registering the issuance under the Securities Act of 2,569,292 shares (the "Shares") of the Company's common stock, par value $0.005, under the Company's Restated 2020 Stock Incentive Plan, as amended (the "2020 Plan").

We have examined the originals, photocopies, certified copies or other evidence of such records of the Company, certificates of officers of the Company and public officials, and other documents as we have deemed relevant and necessary as a basis for the opinion hereinafter expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as certified copies or photocopies and the authenticity of the originals of such latter documents.

Based on our examination mentioned above, we are of the opinion that the Shares, when issued and delivered in accordance with the terms of the 2020 Plan, will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement, and further consent to the reference to us in the Registration Statement. In giving the foregoing consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act, or the rules and regulations of the Securities and Exchange Commission.

Very truly yours,

*/s/ Sichenzia Ross Ference Carmel LLP*

Sichenzia Ross Ference Carmel LLP

1185 AVENUE OF THE AMERICAS \| 31ST FLOOR \| NEW YORK, NY \| 10036

T (212) 930-9700 \| F (212) 930-9725 \| WWW.SRFC.LAW

## Exhibit 23.2

**Exhibit 23.2**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We have issued our report dated March 12, 2025 with respect to the consolidated financial statements of Ernexa Therapeutics Inc. (formerly known as Eterna Therapeutics Inc.) included in the Annual Report on Form 10-K for the year ended December 31, 2024, which is incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement.

 

*/s/ Grant Thornton LLP*

Iselin, New Jersey

June 11, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

**Ernexa Therapeutics Inc.**

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security**<br>**Type** | **Security Class**<br>**Title** | <br>**Amount** <br>**Registered<sup>(1)</sup>** | <br>**Proposed Maximum Aggregate Offering Price Per** <br>**Share<sup>(2)</sup>** | <br>**Fee Calculation**<br>**Rule** | **Maximum**<br> **Aggregate Offering**<br>**Price** | **Fee**<br>**Rate** | **Amount of**<br> **Registration**<br>**Fee** |
| Equity | Common Stock | 2569292 | $0.18 | 457(c) and 457(h) | $462472.56 | 0.0001531 | $70.80 |
|  | **Total Offering Amounts** | 2569292 | $0.18 | 457(c) and 457(h) | $462472.56 | 0.0001531 | $70.80 |
|  | **Total Fees Previously Paid** |  |  |  |  |  |  |
|  | **Total Fee Offsets** |  |  |  |  |  |  |
|  | **Net Fee Due** |  |  |  |  |  | $70.80 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The number of shares of common
 stock, par value $0.005 per share ("Common Stock"), of Ernexa Therapeutics Inc. (the "Registrant") stated above
 is for additional shares of Common Stock available for issuance under the Registrant's Restated 2020 Stock Incentive Plan, as
 amended (the "Plan"). The maximum number of shares which may be sold upon the exercise of options or issuance of stock-based
 awards granted under the Plan are subject to adjustment in accordance with certain anti-dilution and other provisions of the Plan.
 Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration
 statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant
 or otherwise issuable after the operation of any such anti-dilution and other provisions.

(2) Estimated solely for the
 purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities
 Act. The offering price per share and the aggregate offering price for shares reserved for future grant or issuance under the Plan
 are based on the average of the high and the low price of Registrant's Common Stock as reported on The Nasdaq Capital Market
 as of a date (June 4, 2025) within five business days prior to filing this Registration Statement.